drugset / Trial / NCT05214391
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 80 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |